Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRKR)

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

GlobeNewswire February 8, 2022

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

GlobeNewswire January 19, 2022

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

PR Newswire December 9, 2021

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

PR Newswire November 18, 2021

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

PR Newswire November 10, 2021

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

PR Newswire September 7, 2021

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

PR Newswire August 19, 2021

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

PR Newswire August 10, 2021

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

PR Newswire July 28, 2021

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

PR Newswire July 6, 2021

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

PR Newswire June 16, 2021

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

PR Newswire May 12, 2021

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021

PR Newswire April 29, 2021

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

PR Newswire April 27, 2021

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

PR Newswire March 16, 2021

Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

PR Newswire March 12, 2021

Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire March 11, 2021

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

PR Newswire March 9, 2021

Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

PR Newswire March 3, 2021

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

PR Newswire January 13, 2021